NXE0033744
/ Nxera Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 20, 2024
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
(GlobeNewswire)
- "Sosei Group Corporation...announces it has dosed the first subject in a Phase 1 trial evaluating its novel EP4 receptor agonist, HTL0033744 (HTL’744) for the treatment of Inflammatory Bowel Disease (IBD)....The trial will be conducted in the UK and initial data read-outs are anticipated from 2025."
P1 data • Trial status • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1